Results 51 to 60 of about 2,000,650 (198)
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi +10 more
wiley +1 more source
ABSTRACT Autoinflammatory disorders (AIDs) are a clinically heterogeneous group of inborn errors of immunity primarily caused by dysregulation in the innate immune system. Clinical diagnosis is often challenging due to clinical heterogeneity and the overlapping phenotypes with other inborn errors of immunity and monogenic conditions that mimic AIDs ...
Vaishnavi Ashok Badiger +28 more
wiley +1 more source
Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study [PDF]
We determined whether any individual cancers are increased or decreased in a cohort of 595 patients with systemic lupus erythematosus (SLE) followed for up to 32 years at the University College London Hospitals Lupus Clinic, looking for any associated ...
Kenu, E, Dey, D, Isenberg, DA
core
Autoantibodies against complement C1q in systemic lupus erythemathosus [PDF]
Complement and C1q, the first component of the classical pathway of activation of the complement system, are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), a systemic autoimmune disease.
Bigler, Cornelia
core +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis [PDF]
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.
Hartley, Louise +17 more
core +1 more source
Outcome of Early Onset Systemic Lupus Erythmatosus - A Tertiary Care Study
Objective: To evaluate the outcome of early onset systemic lupus erythematosus at tertiary care centre. Study Design: A cross sectional study. Place and Duration of Study: Combined Military Hospital, Kharian Pakistan, from Feb 2021 to Jan 2024 ...
Iffat Rafique +5 more
doaj +1 more source
JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL FEATURES AND CURRENT DIAGNOSTIC APPROACHES
Systemic lupus erythematosus (SLE) is an autoimmune disease with various organs and systems involved in the pathological process, with an unpredictable course, a risk for life-threatening conditions, and an onset from childhood through adolescence in 10 ...
M. I. Kaleda, I. P. Nikishina
doaj +1 more source
Complement Activation Linked to Type II Interferon Signaling in Still Disease
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans +115 more
wiley +1 more source
Review of presentations at the 6th European Lupus Meeting 3-5 March 2005. [PDF]
The 6th European Lupus Meeting was held at the Royal College of Physicians of London and was attended by 450 delegates. The conference brought together leading speakers from Europe and North America who reviewed current knowledge and exciting new ...
Rahman, A +3 more
core

